Temozolomide as a Single Agent or in Combination for Patients with High Risk Refractory or Relapsed Neuroblastoma: Excellent Tolerance and Sustained Disease Responses

被引：0
|
作者：
Metayer, L. [1 ]
Annereau, M. [2 ]
Abbas, R. [3 ]
Hinterlang, M. [2 ]
Schleiermacher, G. [4 ]
Defachelles, A. S. [5 ]
Pasqualini, C. [1 ]
Berlanga, P. [1 ]
Vassal, G. [6 ]
Valteau-Couanet, D. [1 ]
机构：
[1] Gustave Roussy, Dept Childhood & Adolescent Oncol, Villejuif, France
[2] Gustave Roussy, Dept Pharm, Villejuif, France
[3] Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France
[4] Inst Curie, Dept Paediat Oncol, Paris, France
[5] Ctr Oscar Lambret, Dept Paediat Oncol, Lille, France
[6] Gustave Roussy, Dept Clin Res, Villejuif, France
来源：
PEDIATRIC BLOOD & CANCER | 2019年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP052 SIOP
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [31] Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib
    Jakubowiak, Andrzej J.
    Martin, Thomas
    Singhal, Seema B.
    Wang, Michael
    Vij, Ravi
    Jagannath, Sundar
    Lonial, Sagar
    Kukreti, Vishal
    Buadi, Francis
    Bray, Lauren
    Vallone, Marcy
    Kauffman, Michael
    Orlowski, Robert Z.
    Siegel, David Samuel diCapua
    BLOOD, 2010, 116 (21) : 809 - 809
  • [32] RESPONSES TO SINGLE-AGENT CARFILZOMIB (CFZ) ARE NOT AFFECTED BY CYTOGENETICS IN PATIENTS (PTS) WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (R/R MM)
    Jakubowiak, A. J.
    Martin, T.
    Singhal, S.
    Wang, M.
    Vij, R.
    Jagannath, S.
    Lonial, S.
    Kukreti, V.
    Buadi, F.
    Kunkel, L.
    Bray, L.
    Vallone, M.
    Orlowski, R. Z.
    Siegel, D. S.
    ANNALS OF ONCOLOGY, 2011, 22 : 122 - 122
  • [33] SINGLE AGENT HIGH DOSE MELPHALAN PRIOR TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN PEDIATRIC PATIENTS WITH RELAPSED AND REFRACTORY HODGKIN LYMPHOMA
    Guilcher, Gregory
    Lewis, Victor
    Stewart, Douglas
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 843 - 843
  • [34] Preliminary experience of ex-vivo expanded allogeneic universal donor TGFbi NK cell infusions in combination with irinotecan, temozolomide, and dinutuximab in patients with relapsed or refractory neuroblastoma: The Allo - STING trial
    Ranalli, Mark A.
    Shah, Nilay
    Skeens, Micah
    Streby, Keri A.
    Lamb, Margaret
    Cole, Lindsay A.
    Lee, Dean Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia
    Visco, Carlo
    Finotto, Silvia
    Pomponi, Fabrizio
    Sartori, Roberto
    Laveder, Francesco
    Trentin, Livio
    Paolini, Rossella
    Di Bona, Eros
    Ruggeri, Marco
    Rodeghiero, Francesco
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (04) : 289 - 293
  • [36] Naxitamab-related adverse events within and across treatment cycles in patients with relapsed/refractory (R/R) high-risk neuroblastoma
    Mora, Jaume
    Chan, Godfrey C.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa
    Rubio-San-Simon, Alba
    Eldridge, James
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Survival outcomes in patients with high-risk neuroblastoma (HRNB) in remission after relapsed or refractory treatment receiving eflornithine (DFMO) maintenance.
    Sholler, Giselle Linda Saulnier
    Ferguson, William
    Bergendahl, Genevieve
    Clinch, Thomas
    Kraveka, Jacqueline M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Tandem High-Dose 131I-MIBG Therapy For Paediatric Patients With Relapsed-Refractory High Risk Neuroblastoma: A Dosimetry Based Treatment
    Altini, C.
    Villani, M.
    Cassano, B.
    Pizzoferro, M.
    Serra, A.
    Castellano, A.
    Cannata, V.
    Garganese, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S689 - S689
  • [39] Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma
    Vij, Ravi
    Wang, Michael
    Jagannath, Sundar
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    Kavalerchik, Edward
    Huang, Mei
    Siegel, David S.
    BLOOD, 2013, 122 (21)
  • [40] THE IMPACT OF POST-INDUCTION TREATMENT ON RESPONSE AND OUTCOMES OF PATIENTS WITH HIGH-RISK NEUROBLASTOMA WITH REFRACTORY DISEASE.
    Siddiqui, A.
    Desai, A.
    Cohn, S.
    Gao, G.
    Oppong, A.
    Yuan, C.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S52 - S52
12345